Solid Biosciences Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value
Solid Biosciences Inc. (SLDB) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value of $5.04 per share for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue · last filed 2026-08-06
- Solid Biosciences Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2026-06-30 was $5.04, a 31.25% increase year-over-year.
- Solid Biosciences Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2026-03-31 was $5.22, a 53.98% increase year-over-year.
- Solid Biosciences Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2025-09-30 was $5.31, a 29.76% decline year-over-year.
- Solid Biosciences Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2025-06-30 was $3.84, a 41.10% decline year-over-year.
- Solid Biosciences Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2025 was $4.77, a 31.47% decline from fiscal 2024.
- Solid Biosciences Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2024 was $6.96, a 46.22% increase from fiscal 2023.
- Solid Biosciences Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2023 was $4.76.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 12 month |
|---|---|---|---|---|
| 2026-06-30 | $5.04 10-Q · filed 2026-08-06 | $5.17 10-Q · filed 2026-08-06 | ||
| 2026-03-31 | $5.22 10-Q · filed 2026-05-12 | |||
| 2025-12-31 | $4.77 10-K · filed 2026-03-19 | |||
| 2025-09-30 | $5.31 10-Q · filed 2025-11-03 | $4.77 10-Q · filed 2025-11-03 | ||
| 2025-06-30 | $3.84 10-Q · filed 2026-08-06 | $3.83 10-Q · filed 2026-08-06 | ||
| 2025-03-31 | $3.39 10-Q · filed 2026-05-12 | |||
| 2024-12-31 | $6.96 10-K · filed 2026-03-19 | |||
| 2024-09-30 | $7.56 10-Q · filed 2025-11-03 | $6.96 10-Q · filed 2025-11-03 | ||
| 2024-06-30 | $6.52 10-Q · filed 2025-08-12 | $6.91 10-Q · filed 2025-08-12 | ||
| 2024-03-31 | $7.03 10-Q · filed 2025-05-15 | |||
| 2023-12-31 | $4.76 10-K · filed 2025-03-06 | |||
| 2023-09-30 | $3.28 10-Q · filed 2024-11-06 | $5.04 10-Q · filed 2024-11-06 | ||
| 2023-06-30 | $5.06 10-Q · filed 2024-08-13 | $5.08 10-Q · filed 2024-08-13 | ||
| 2018-09-30 | $20.13 10-Q · filed 2018-11-13 | |||
| 2018-06-30 | $16.91 10-Q · filed 2018-08-10 | |||
| 2018-03-31 | $17.68 10-Q · filed 2018-05-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Aura Biosciences, Inc. (AURA) | United States | $0.639B | -5.61 |
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| Allogene Therapeutics, Inc. (ALLO) | United States | $0.574B | -4.33 |
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |